Exabis Library
Welcome to the e-CCO Library!
OP03: Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s Disease: Long-term follow up of the LIR!C trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP03: Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP04 Long-term outcomes after ileocolonic resection in Crohn’s disease according to the severity of early endoscopic recurrence
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP04: Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP04: Long-term outcomes after ileocolonic resection in Crohn’s Disease according to severity of early endoscopic recurrence
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP04: Long-term outcomes after ileocolonic resection in Crohn’s Disease according to severity of early endoscopic recurrence
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP04: Turning sweet in inflammatory bowel disease: glycans as novel immunomodulators of T-cell-mediated immune response
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP04: Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP05 Validation of the Lémann index in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP05: Crohn’s disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in mild-to-moderate active paediatric Crohn’s disease: a prospective randomised controlled trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP05: High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP05: High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP05: Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP05: Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP05: Validation of the Lémann Index in Crohn’s Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP05: Validation of the Lémann Index in Crohn’s Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1